

Vuity[™]
(pilocarpine HCl ophthalmic solution) 1.25%

A QUICK LOOK

Potential Presbyopia Patients

INDICATION

VUITY[™] (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

Please see additional Important Safety Information in this brochure.

Please see full Prescribing Information.

COULD THESE BE YOUR PRESBYOPIA PATIENTS?



Emma Emmetrope

45, Accountant

- 1 Analyzes documents, inputs numbers and data
- 2 Never been to an eye care professional
- 3 Starting to squint, enlarge text on devices, and increase brightness when reading



DIAGNOSIS:
moderate
presbyopia

Not actual patient.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.

Please see additional Important Safety Information in this brochure.

Please see full [Prescribing Information](#).


(pilocarpine HCl ophthalmic solution) 1.25%

COULD THESE BE YOUR PRESBYOPIA PATIENTS?



Lisa **LASIK**

49, Hairstylist

- 1 Wears reading glasses when cutting hair and viewing styling products
- 2 Had LASIK 10 years ago to correct myopia
- 3 Struggles to see up close
- 4 Seeks flexibility in treatment options

DCNVA
20/63
[J8]
+1.75 D

DIAGNOSIS:
moderate
presbyopia

Not actual patient.

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

Please see additional Important Safety Information in this brochure.

Please see full [Prescribing Information](#).

Vuity[™]
(pilocarpine HCl ophthalmic solution) 1.25%

COULD THESE BE YOUR PRESBYOPIA PATIENTS?



Henry Hyperope

42, Server

- 1 Works in a dimly lit restaurant, reviews wine list, and makes recommendations for customers
- 2 First showed signs of presbyopia at the age of 40
- 3 Holds items farther away and uses a flashlight to read the menu

DCNVA
20/40
[J3]
+0.75 D

DIAGNOSIS:
mild
presbyopia

Not actual patient.

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.

Please see additional Important Safety Information in this brochure.

Please see full [Prescribing Information](#).

Vuity[™]
(pilocarpine HCl ophthalmic solution) 1.25%

Vuity[™]
(pilocarpine HCl ophthalmic solution) 1.25%



FOR AN IN-DEPTH LOOK
visit VuityPro.com

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

Please see additional Important Safety Information in this brochure.

Please see full Prescribing Information.



VUITY[™] and its design are registered trademarks of Allergan, Inc., an AbbVie company.
© 2021 AbbVie. All rights reserved. US-VUI-210173 December 2021